NEW YORK (GenomeWeb News) – Nicox, a company specializing in ophthalmic therapies and diagnostics, will market Sequenom's RetnaGene AMD test in North America, the partners said today.

Under the terms of the agreement, Nicox has gained exclusive North American promotional rights to Sequenom Laboratories' RetnaGene laboratory-developed test, which evaluates a patient's risk of AMD disease progression within 2, 5 and 10 years.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.